Loratadine and montelukast administered in combination produce decongestion in an experimental feline model of nasal congestion

American Journal of Rhinology and Allergy

Volumn 23, Issue 6, 2009, Pages

  McLeod, Robbie L ^a   Mingo, Garfield G ^a   Xu, Xiaoying ^a   Palamanda, Jairam ^a   Hunter, John C ^a   Jia, Yanlin ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Acoustic rhinometry; Allergic rhinitis; Antihistamine; Compound 48 80; Desloratadine; Histamine H1 antagonist; Leukotriene receptor antagonist; Loratadine; Montelukast; Nasal decongestion

Indexed keywords

DESLORATADINE; LORATADINE; MONTELUKAST; PSEUDOEPHEDRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG POTENTIATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NOSE CAVITY; NOSE CONGESTION; RHINOMETRY;

ACETATES; ANIMALS; CATS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LEUKOTRIENE ANTAGONISTS; LORATADINE; MALE; NASAL CAVITY; NASAL OBSTRUCTION; NASAL PROVOCATION TESTS; PSEUDOEPHEDRINE; QUINOLINES; RHINOMETRY, ACOUSTIC; TREATMENT OUTCOME;

EID: 76149142763     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2009.23.3365     Document Type: Article

References (41)

1. Naclerio RM. Allergic rhinitis. N Engl J Med 325:860-869, 1991.
2. Law AW, Reed SD, Sundy JS, and Schulman KA. Direct costs of allergic rhinitis in the United States: Estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 111:296-300, 2003.
3. Engler DB, and Grant JA. Allergic rhinitis: A practical approach. Hosp Pract 26:105-108, 1991.
4. Ferguson BJ. Influences of allergic rhinitis on sleep. Otolaryngol Head Neck Surg 130:617-629, 2004.
5. Mansfield LE, and Posey CR. Daytime sleepiness and cognitive performance improve in seasonal allergic rhinitis treated with intranasal fluticasone propionate. Allergy Asthma Proc 28:226-229, 2007.
6. Blaiss MS. Allergic rhinoconjunctivitis: Burden of disease. Allergy Asthma Proc 28:393-397, 2007.
7. Al Suleimani YM, and Walker MJ. Allergic rhinitis and its pharmacology. Pharmacol Ther 114:233-260, 2007.
8. Raphel GD, Igarashi Y, White MV, and Kaliner MA. The pathophysiology of rhinitis. J Allergy Clin Immunol 88:33-42, 1991.
9. Doyle WJ, Boehm S, and Skoner DP. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. J Allergy Clin Immunol 86:924-935, 1990.
10. Fujikura T, Shimosawa T, and Yakuo I. Regulatory effect of histamine H1 receptor antagonist on the expression of messenger RNA encoding CC chemokines in the human nasal mucosa. J Allergy Clin Immunol 107:123-128, 2001.
11. MacGlashan D Jr. Histamine: A mediator of inflammation. J Allergy Clin Immunol 112:S53-S59, 2003.
12. Burks T.F. Histamine and antihistamines. In Human Pharmacology Molecular to Clinical. Wingrd LB, Brody TT, Larner J, and Schwartz A (Eds). St. Louis, MO: Mosby-Year Book, Inc., 776-788, 1991.
13. Burkhalter A, Julius D, and Frick OL. Histamine, serotonin and ergot alkaloids. In Basic and Clinical Pharmacology. Katzung BG (Ed). Stamford, CT: Applton and Lange, 251-275, 1995.
14. 1-receptor antagonists: Clinical pharmacology and use in allergic disease. Pediatr Clin North Am 30:899-914, 1983.
15. Howarth PH, Emanuel MB, and Holgate ST. Astemizole, a potent histamine H1 receptor antagonist: Effects in a allergic rhinoconjunctivitis on antigen and histamine induce skin wheal responses and relationship to serum levels. Br J Clin Pharmacol 18:1-8, 1984.
16. Boner AL, Miglioranzi P, Richelli C, et al. Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis. Allergy 44:437-441, 1989.
17. Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 313:65-70, 1985.
18. Brink C, Dahlén SE, Drazen J, et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 55:195-227, 2003.
19. Dahlén SE. Treatment of asthma with antileukotrienes: First line or last resort therapy? Eur J Pharmacol 533:40-56, 2006.
20. Montuschi P, Sala A, Dahlén SE, and Folco G. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov Today 12:404-412, 2007.
21. Borish L. The role of leukotrienes in upper and lower airway inflammation and the implications for treatment. Ann Allergy Asthma Immunol 88:16-22, 2002.
22. Haberal I, and Corey JP. The role of leukotrienes in nasal allergy. Otolaryngol Head Neck Surg 129:274-279, 2003.
23. Bisgaard H, Olsson P, and Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 16:289-297, 1986.
24. Creticos PS, Peters SP, Adkinson NF Jr, et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 310:1626-1630, 1984.
25. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 323:1745-1748, 1990.
26. Donnelly AL, Glass M, Minkwitz MC, and Casale TB. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 151:1734-1739, 1995.
27. van Adelsberg J, Philip G, Pedinoff AJ, et al. Montelukast Fall Rhinitis Study Group. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 58:1268-1276, 2003.
28. Ueda T, Takeno S, Furukido K, et al. Leukotriene receptor antagonist pranlukast suppresses eosinophil infiltration and cytokine production in human nasal mucosa of perennial allergic rhinitis. Ann Otol Rhinol Laryngol 112:955-961, 2003.
29. Santos CB, Hanks C, McCann J, et al. The role of montelukast on perennial allergic rhinitis and associated sleep disturbances and daytime somnolence. Allergy Asthma Proc 29:140-145, 2008.
30. Philip G, Williams-Herman D, Patel P, et al. Efficacy of montelukast for treating perennial allergic rhinitis. Allergy Asthma Proc 28:296-304, 2007.
31. Lagunoff D, Martin TW, and Read G. Agents that release histamine from mast cells. Annu Rev Pharmacol Toxicol 23:331-351, 1983.
32. McLeod RL, Mingo G, Herczku C, et al. Changes in nasal resistance and nasal geometry using pressure and acoustic rhinometry in a feline model of nasal congestion. Am J Rhinol 13:375-383, 1999.
33. Straszek SP, McLeod RL, Hey JA, et al. Comparison of feline nasal cavity dimensions measured by acoustic rhinometry and nasal casts. Am J Rhinol 17:233-239, 2003.
34. Erickson CH, McLeod RL, Mingo GG, et al. Comparative oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine. Am J Rhinol 15:83-90, 2001.
35. Koss MC, Yu Y, Hey JA, and McLeod RL. Measurement of nasal patency in anesthetized and conscious dogs. J Appl Physiol 92:617-621, 2002.
36. Kurowski M, Kuna P, and Górski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: Influence on clinical symptoms and nasal allergic inflammation. Allergy 59:280-288, 2004.
37. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 105:917-922, 2000.
38. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 88:592-600, 2002.
39. Ciebiada M, Górska-Ciebiada M, DuBuske LM, and Górski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol 97:664-671, 2006.
40. Knorr B, Larson P, Nguyen HH, et al. Montelukast dose selection in 6- to 14-year-olds: Comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol 39:786-793, 1999.
41. Xu HR, Li XN, Chen WL, and Chu NN. Simultaneous determination of desloratadine and its active metabolite 3-hydroxydesloratadine in human plasma by LC/MS/MS and its application to pharmacokinetics and bioequivalence. J Pharm Biomed Anal 45:659-666, 2007.